Loading cancer entity…
Loading cancer entity…
Variants & evidence
14 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|
| HLA-A *02:01P + HLA-A *02:02P + HLA-A *02:03P + HLA-A *02:06P + MAGEA4 ExpressionHLA-AMAGEA41 | |||||||
| Afamitresgene Autoleucel | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID12138In cohort 1 of this non-randomised, phase 2 trial (SPEARHEAD-1), 52 patients, aged, 16-75, with synovial sarcoma (n = 44) and myxoid round cell liposarcoma (n=8) harboring HLA-A*02 and MAGE-A4 were tr… (full text at CIViC) PMID 38554725 · D'Angelo et al., 2024 · Open in CIViC | civic |
| SMARCB1 Underexpression1 | |||||||
| Tazemetostat | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID1739Treatment with tazemetostat , a small-molecule inhibitor of EZH2, results in concentration-dependent cell growth inhibition and cell death specifically in SS18-SSX-positive, SMARCB1-deficient synovial… (full text at CIViC) PMID 27391784 · Kawano et al., 2016 · Open in CIViC | civic |
| SSX1 Fusion7 | |||||||
| (diagnostic) | Diagnostic | A | Supports Positive | 4 | accepted | EID1063A t(X;18) translocation resulting in the fusion SYT-SSX (SS18-SSX1 or SS18-SSX2) is detected cytogenetically in over 90% of synovial sarcomas, regardless of histologic subtype. The prevalence of this … (full text at CIViC) PMID 11607825 · Ladanyi, 2001 · Open in CIViC | civic |
| 〃 | Diagnostic | B | Supports Positive | 4 | accepted | EID1069In this review, the author summarize the role of this fusion in diagnosis of synovial sarcomas. Cytogenetic studies have repeatedly demonstrated the t(X;18)(p11;q11) translocation in approximately 90%… (full text at CIViC) PMID 11122430 · Pfeifer et al., 2000 · Open in CIViC | civic |
| 〃 | Diagnostic | B | Supports Positive | 4 | accepted | EID1070In this study, 141 spindle cell sarcomas were evaluated for the presence of t(X;18) by RT-PCR. 85% of the synovial sarcomas were positive for this event. The study did not indicate the specific fusion… | |
| SSX2 Fusion4 | |||||||
| (diagnostic) | Diagnostic | A | Supports Positive | 4 | accepted | EID1064A t(X;18) is detected cytogenetically in over 90% of synovial sarcomas, regardless of histologic subtype. This translocation results primarily in two fusions. SYT-SSX1 (aka SS18-SSX1) and SYT-SSX2 (ak… (full text at CIViC) PMID 11607825 · Ladanyi, 2001 · Open in CIViC | civic |
| 〃 | Diagnostic | B | Supports Positive | 3 | accepted | EID1066A characteristic SYT-SSX fusion gene resulting from the chromosomal translocation t(X;18)(p11;q11) is detectable in almost all synovial sarcomas. SYT (aka SS18) pairs with various 3' partners know as … (full text at CIViC) PMID 9428816 · Kawai et al., 1998 · Open in CIViC | civic |
| (prognostic) | Prognostic | B | Supports Better Outcome | 3 | accepted | EID1067In this study, SYT-SSX fusion transcripts (SS18-SSX1 and SS18-SSX2) were detected in 29 (64%) and 16 (36%) of the tumors, respectively. There was a significant relationship (P=0.003) between histologi… | |
| SSX4 Fusion1 | |||||||
| (diagnostic) | Diagnostic | C | Supports Positive | 2 | accepted | EID1074Three synovial sarcomas were assayed for SYT-SSX fusion messenger RNA by nested RT-PCR. In a single case an SYT-SSX4 (SS18-SSX4) fusion was detected. The majority of synovial sarcomas are characterize… (full text at CIViC) PMID 10359553 · Skytting et al., 1999 · Open in CIViC | civic |
Data updated 24 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
PMID 11144931 · O'Sullivan et al., 2000 · Open in CIViC
| civic |
| (prognostic) | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID1072This study collected data on SYT-SSX fusion type, pathology, and clinical course in a retrospective multi-institutional study of 243 patients (age range, 6-82) with synovial sarcoma. SYT-SSX1 and SYT-… (full text at CIViC) PMID 11782370 · Ladanyi et al., 2002 · Open in CIViC | civic |
| (diagnostic) | Diagnostic | B | Supports Positive | 4 | accepted | EID12122This study used RT-PCR assays to screen tumor blocks for SS18::SSX1 fusion transcripts in 134 synovial sarcomas cases. 194 normal tissue and samples from unrelated tumor types were used as negative co… (full text at CIViC) PMID 17334349 · Amary et al., 2007 · Open in CIViC | civic |
| 〃 | Diagnostic | B | Supports Positive | 3 | accepted | EID1065A characteristic SYT-SSX fusion gene resulting from the chromosomal translocation t(X;18)(p11;q11) is detectable in almost all synovial sarcomas. SYT (aka SS18) pairs with various 3' partners know as … (full text at CIViC) PMID 9428816 · Kawai et al., 1998 · Open in CIViC | civic |
| (prognostic) | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID1068In this study, SYT-SSX fusion transcripts (SS18-SSX1 and SS18-SSX2) were detected in 29 (64%) and 16 (36%) of the tumors, respectively. There was a significant relationship (P=0.003) between histologi… (full text at CIViC) PMID 9428816 · Kawai et al., 1998 · Open in CIViC | civic |
PMID 9428816 · Kawai et al., 1998 · Open in CIViC
| civic |
| 〃 | Prognostic | B | Supports Better Outcome | 3 | accepted | EID1073This study collected data on SYT-SSX fusion type, pathology, and clinical course in a retrospective multi-institutional study of 243 patients (age range, 6-82) with synovial sarcoma. SYT-SSX1 and SYT-… (full text at CIViC) PMID 11782370 · Ladanyi et al., 2002 · Open in CIViC | civic |